Material and methods for the growth of hematopoietic stem cells
First Claim
Patent Images
1. A cell culture medium for expanding a population of stem and progenitor cells comprising basic fibroblast growth factor (bFGF;
- 1-5 ng/ml), erythropoietin (EPO;
1-6 units/ml), Flt-3/Flk-2 ligand (2-10 ng/ml), interleukin-11 (IL-11;
0.05-0.2 ng/ml), interleukin-6 (IL-6;
0.1-0.5 ng/ml), platelet-derived endothelial cell growth factor (PD-ECGF;
1-4 ng/ml), thrombospondin (5-20 ng/ml), and thrombopoietin (TPO;
0.5-2 ng/ml).
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides populations of expanded CD34-expressing cells and methods of use. Particular embodiments provide for defined culture media useful for growing these cells, and grafts comprising these cells. The invention finds use in methods for reconstituting, repairing, and regenerating tissue damage.
-
Citations
4 Claims
-
1. A cell culture medium for expanding a population of stem and progenitor cells comprising basic fibroblast growth factor (bFGF;
- 1-5 ng/ml), erythropoietin (EPO;
1-6 units/ml), Flt-3/Flk-2 ligand (2-10 ng/ml), interleukin-11 (IL-11;
0.05-0.2 ng/ml), interleukin-6 (IL-6;
0.1-0.5 ng/ml), platelet-derived endothelial cell growth factor (PD-ECGF;
1-4 ng/ml), thrombospondin (5-20 ng/ml), and thrombopoietin (TPO;
0.5-2 ng/ml). - View Dependent Claims (2)
- 1-5 ng/ml), erythropoietin (EPO;
- 3. A method of producing an expanded population of hematopoietic stem and progenitor cells expressing the CD34 cell surface marker, said method comprising culturing a population of CD34+ stem and progenitor cells in a cell culture medium comprising bFGF (1-5 ng/ml), EPO (1-6 units/ml), Flt-3/Flk-2 ligand (2-10 ng/ml), IL-11 (0.05-0.2 ng/ml), IL-6 (0.1-0.5 ng/ml), PD-ECGF (1-4 ng/ml), thrombospondin (5-20 ng/ml), and TPO (0.5-2 ng/ml), thereby producing an expanded population of hematopoietic stem and progenitor cells expressing the CD34 cell surface marker.
Specification